Analysts See $-0.41 EPS for Advaxis, Inc. (ADXS); Shorts at Oak Valley Bancorp (ca) (OVLY) Raised By 207.14%

June 6, 2018 - By Marie Mckinney

Oak Valley Bancorp (NASDAQ:OVLY) Logo

Analysts expect Advaxis, Inc. (NASDAQ:ADXS) to report $-0.41 EPS on June, 7 before the open.They anticipate $0.10 EPS change or 19.61% from last quarter’s $-0.51 EPS. After having $-0.49 EPS previously, Advaxis, Inc.’s analysts see -16.33% EPS growth. It closed at $1.67 lastly. It is down 79.31% since June 6, 2017 and is downtrending. It has underperformed by 91.88% the S&P500. Some Historical ADXS News: ; 11/05/2018 – Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent; 20/04/2018 – DJ Advaxis Inc, Inst Holders, 1Q 2018 (ADXS); 17/04/2018 – Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting; 12/03/2018 – ADXS, $AZN.GB: $ADXS Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab) – ! $AZN.GB $ADXS; 11/05/2018 – ADVAXIS REPORTS ADXS-NEO POTENTIAL TO GENERATE IMMUNE RESPONSES; 26/03/2018 – Advaxis Presenting at Conference Apr 16; 23/04/2018 – ADVAXIS INC – KENNETH BERLIN HAS BEEN APPOINTED AS PRESIDENT AND CHIEF EXECUTIVE OFFICER; 17/04/2018 – Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cance; 12/03/2018 – ADVAXIS – ENROLLMENT AND DOSING IN ALL OTHER ADVAXIS CLINICAL PROGRAMS ARE UNAFFECTED AT THIS TIME; 12/03/2018 ADVAXIS SAYS FDA PLACED PHASE 1/2 STUDY ON CLINICAL HOLD

Oak Valley Bancorp (ca) (NASDAQ:OVLY) had an increase of 207.14% in short interest. OVLY’s SI was 4,300 shares in June as released by FINRA. Its up 207.14% from 1,400 shares previously. With 7,200 avg volume, 1 days are for Oak Valley Bancorp (ca) (NASDAQ:OVLY)’s short sellers to cover OVLY’s short positions. The SI to Oak Valley Bancorp (ca)’s float is 0.07%. The stock decreased 0.65% or $0.14 during the last trading session, reaching $21.46. About 8,491 shares traded or 11.68% up from the average. Oak Valley Bancorp (NASDAQ:OVLY) has risen 46.01% since June 6, 2017 and is uptrending. It has outperformed by 33.44% the S&P500. Some Historical OVLY News: ; 29/05/2018 – Oak Valley Community Bank Announces Business Development Officer and Branch Manager Hiring; 18/04/2018 Oak Valley Bancorp 1Q EPS 35c; 14/05/2018 – Oak Valley Community Bank Announces Commercial Banking Market Manager Promotions; 19/04/2018 – DJ Oak Valley Bancorp, Inst Holders, 1Q 2018 (OVLY)

Since December 29, 2017, it had 0 buys, and 3 selling transactions for $20,259 activity. Shares for $94 were sold by LOMBARDO ANTHONY A on Friday, February 2. Bonstein Sara sold 5,224 shares worth $16,612. PETIT ROBERT also sold $3,553 worth of Advaxis, Inc. (NASDAQ:ADXS) shares.

More news for Advaxis, Inc. (NASDAQ:ADXS) were recently published by: Businesswire.com, which released: “Data Highlighting Advaxis’ ADXS-PSA Presented at ASCO Annual Meeting” on June 01, 2018. Benzinga.com‘s article titled: “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” and published on June 03, 2018 is yet another important article.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The company has market cap of $87.36 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. It currently has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

Among 4 analysts covering Advaxis (NASDAQ:ADXS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Advaxis has $40 highest and $5 lowest target. $20.25’s average target is 1112.57% above currents $1.67 stock price. Advaxis had 10 analyst reports since September 11, 2015 according to SRatingsIntel. On Wednesday, May 31 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm earned “Overweight” rating on Tuesday, September 22 by Barclays Capital. As per Wednesday, March 14, the company rating was maintained by H.C. Wainwright. The stock of Advaxis, Inc. (NASDAQ:ADXS) earned “Buy” rating by H.C. Wainwright on Wednesday, December 27. H.C. Wainwright maintained it with “Buy” rating and $2300 target in Wednesday, June 14 report. Guggenheim initiated it with “Buy” rating and $30.0 target in Friday, September 11 report. The stock of Advaxis, Inc. (NASDAQ:ADXS) has “Buy” rating given on Monday, June 12 by Cantor Fitzgerald. On Tuesday, March 13 the stock rating was maintained by Cantor Fitzgerald with “Overweight”. The rating was maintained by Cantor Fitzgerald on Thursday, July 6 with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, November 8.

Investors sentiment increased to 1.14 in Q1 2018. Its up 0.02, from 1.12 in 2017Q4. It is positive, as 10 investors sold Advaxis, Inc. shares while 18 reduced holdings. 9 funds opened positions while 23 raised stakes. 16.99 million shares or 11.99% more from 15.17 million shares in 2017Q4 were reported. Amer Interest Gp has invested 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Legal & General Public Ltd owns 5,432 shares or 0% of their US portfolio. 674,406 were reported by State Street. Bancorp Of America De holds 0% or 5,667 shares. Royal Commercial Bank Of Canada reported 51 shares. Jfs Wealth Advisors Ltd Llc accumulated 500 shares or 0% of the stock. Boothbay Fund Mgmt holds 0.01% or 67,987 shares in its portfolio. Raymond James Fincl Advsr owns 16,402 shares. Moreover, Syntal Cap Partners Ltd Limited Liability Company has 0.01% invested in Advaxis, Inc. (NASDAQ:ADXS) for 10,000 shares. Pub Employees Retirement Association Of Colorado holds 0% or 16,161 shares. Bank Of New York Mellon owns 147,640 shares. Citigroup Inc reported 0% stake. Sg Americas Secs Limited Company accumulated 14,872 shares or 0% of the stock. Geode Cap Mgmt Limited Liability Corp holds 285,323 shares or 0% of its portfolio. Perceptive Advisors Limited Liability Corp has 0.07% invested in Advaxis, Inc. (NASDAQ:ADXS) for 1.50M shares.

Oak Valley Bancorp operates as the holding firm for Oak Valley Community Bank that provides banking services and products for individuals and business enterprises in Oakdale, California and the surrounding areas. The company has market cap of $175.61 million. It operates through two divisions, Retail Banking and Commercial Banking. It has a 19.02 P/E ratio. The firm accepts various deposits products, such as checking and savings, negotiable order of withdrawal, money market, health savings, and individual retirement accounts, as well as overdraft protection facilities and certificates of deposit.

Since February 1, 2018, it had 5 buys, and 10 insider sales for $82,669 activity. $64,000 worth of stock was bought by HOLDER H RANDOLPH JR on Friday, May 18. Haidlen Thomas A had bought 94 shares worth $2,040. McCarty Richard A. also sold $21,166 worth of Oak Valley Bancorp (NASDAQ:OVLY) shares. Martin Ronald C. sold $23,049 worth of stock or 1,076 shares. The insider Gilbert James L bought $3,864. $26,250 worth of stock was sold by Harvey David S on Tuesday, May 1. The insider Pelton Janet S bought 5,000 shares worth $101,500.

Advaxis, Inc. (NASDAQ:ADXS) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>